FDA approves first biosimilar to Neulasta to decrease the risk of infection during cancer treatment
- Drugs
- Fulphila (pegfilgrastim-jmdb) · Granulocyte colony-stimulating factor, Neulasta (pegfilgrastim) · Granulocyte colony-stimulating factor
- Condition
- Classical hematology